Membranous Nephropathy Assay for EXT1/EXT2 Autoantibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for membranous nephropathy (MN) are inadequate for detecting autoantibodies to PLA2R-negative patients, and there is a need for improved serological assays to distinguish autoimmune MN from other causes, enhancing diagnostic sensitivity and specificity.
Innovation Solution
A carrier coated with recombinant polypeptides comprising SEQ ID NO: 1 or variants, used in immunoassays to detect autoantibodies to EXT1/EXT2, which are present in MN patients, and a kit comprising these polypeptides for diagnosing MN, including secondary antibodies and controls, allowing differentiation between autoimmune and non-autoimmune MN.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If PLA2R-based serological assay is used for diagnosing MN, then diagnostic simplicity and non-invasiveness are improved, but diagnostic coverage is limited to only 70% of patients (PLA2R-positive cases)
Solution Approach 1:
The patent extends the diagnostic assay from detecting only PLA2R autoantibodies to detecting multiple autoantigens (PLA2R, THSD7A, NELL-1, Semaphorin 3B, EXT1, EXT2) using the same serological platform. This multi-functional approach maintains the simplicity and non-invasive nature of blood-based testing while expanding diagnostic coverage to capture diverse MN subtypes that would otherwise be missed by PLA2R-specific assays alone.
2Reliability
If autoantibodies to multiple autoantigens (PLA2R, THSD7A, NELL-1, Semaphorin 3B, EXT1, EXT2) are detected using serological assays, then diagnostic coverage and accuracy are improved, but assay complexity increases
Solution Approach 1:
The patent divides the complex multi-autoantigen detection task into separate, independent detection modules for each autoantigen (PLA2R, THSD7A, NELL-1, Semaphorin 3B, EXT1, EXT2). Each autoantigen can be detected in separate assay wells or on separate carriers, allowing the complex diagnostic process to be broken down into manageable, standardized units that can be performed systematically without overwhelming complexity.
Solution Approach 2:
The patent combines multiple autoantigen detection capabilities into a single integrated serological assay platform. By using the same basic assay methodology (immunodetection in serum/plasma) for all six autoantigens, the patent merges the simplicity of a single-antigen assay with the comprehensive coverage of multi-antigen detection, achieving high diagnostic accuracy without proportionally increasing procedural complexity.
3Adaptability or versatility
If autoimmune MN is distinguished from non-autoimmune MN through autoantibody detection, then treatment personalization is improved, but diagnostic time and resource investment increase
Solution Approach 1:
The patent performs preliminary detection of multiple autoantigens simultaneously through a single serological assay before treatment decisions are made. By establishing the autoimmune status and specific autoantigen profile early in the diagnostic process, the assay enables treatment personalization to be planned in advance rather than requiring prolonged observation or sequential testing, thereby reducing overall diagnostic time despite the comprehensive nature of the analysis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables the detection of autoantibodies to EXT1/EXT2 in blood samples, improving diagnostic sensitivity for MN and distinguishing autoimmune MN from other causes, thereby guiding targeted treatment strategies.
Implementation Method 1
a carrier coated with a recombinant polypeptide comprising SEQ ID NO: 1... an isolated autoantibody binding specifically to a polypeptide having SEQ ID NO: 1... detecting the presence or absence of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1
Data Source
AI summary
Provided are a diagnostically useful carrier coated with a recombinant polypeptide comprising SEQ ID NO: 1, an isolated autoantibody binding specifically to a polypeptide having SEQ ID NO: 1, a kit comprising the carrier, a method for the diagnosis of a membranous nephropathy (MN) that includes detecting the presence or absence of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 in a liquid sample comprising antibodies from a subject, a use of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 or a polypeptide comprising SEQ ID NO: 1, and a aqueous solution comprising an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1.